A federal panel of health experts in Atlanta has put forward recommendations for expanding RSV vaccinations for adults and introducing a new combination vaccine to protect teenagers against meningitis. This panel, consisting of 15 members, typically guides the Centers for Disease Control and Prevention (CDC) on vaccine utilization.
In a significant shift, the recommendations will be evaluated by Matthew Buzzelli, the CDC’s chief of staff, who does not have a medical background. He stepped into this role amid the agency currently lacking a permanent director. His previous experience is primarily as an attorney, which adds a layer of concern for some regarding medical decisions.
The panel advised that individuals aged 50 to 59 who have health risks such as heart disease, diabetes, or chronic respiratory issues should receive the RSV vaccine. Additionally, they supported a new combination shot developed by GSK that protects against five strains of meningococcal bacteria. This is particularly important as one of the strains has been linked to outbreaks at college campuses about a decade ago.
Moreover, the group suggested a second chikungunya vaccine for Americans aged 12 and older traveling to areas with outbreaks of this mosquito-borne illness, which sees around 100 to 200 cases reported among U.S. travelers every year. There is also a new warning regarding the older chikungunya vaccine, which uses a weakened live virus. The panel recommended that people aged 65 and older carefully consider the risks and benefits, especially after reports of adverse reactions in older individuals post-vaccination.
It remains uncertain how quickly Buzzelli will make a decision on these recommendations. Susan Monarez was appointed as the acting CDC director by the Trump administration and is waiting for Senate confirmation. Until then, she has effectively stepped back from regular duties due to federal laws regarding vacancies, despite her qualifications in microbiology and immunology.
The developments at the CDC highlight the ongoing debate over vaccine policies and the importance of having experienced medical leadership guiding these crucial health decisions.
